Diagnostic value of heart-to-mediastinum ratio in
Amyloid heart disease
SPECT
diagnostic and prognostic application
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
16
06
2022
accepted:
26
11
2022
medline:
28
7
2023
pubmed:
23
12
2022
entrez:
22
12
2022
Statut:
ppublish
Résumé
In transthyretin cardiac amyloidosis (ATTR-CA), We retrospectively included 164 patients who underwent After the exclusion of patients who did not undergo endomyocardial biopsy, 30 patients (15 each with ATTR-CA and without ATTR-CA) were included. The receiver operating characteristic curve used to distinguish ATTR-CA from non-ATTR-CA patients revealed an area under the curve of 0.986 and 0.943, respectively. A H/M ratio of > 1.41 identified ATTR-CA patients with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 100, 93.3, 93.3, and 100%, respectively. Conversely, an H/CL ratio of > 1.3 identified ATTR-CA patients with 100% sensitivity, 40.0% specificity, 62.5% PPV, and 100% NPV. The H/M ratio obtained at 3 hours post-injection has the potential to be a novel indicator for ATTR-CA.
Sections du résumé
BACKGROUND
In transthyretin cardiac amyloidosis (ATTR-CA),
METHODS
We retrospectively included 164 patients who underwent
RESULTS
After the exclusion of patients who did not undergo endomyocardial biopsy, 30 patients (15 each with ATTR-CA and without ATTR-CA) were included. The receiver operating characteristic curve used to distinguish ATTR-CA from non-ATTR-CA patients revealed an area under the curve of 0.986 and 0.943, respectively. A H/M ratio of > 1.41 identified ATTR-CA patients with a sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 100, 93.3, 93.3, and 100%, respectively. Conversely, an H/CL ratio of > 1.3 identified ATTR-CA patients with 100% sensitivity, 40.0% specificity, 62.5% PPV, and 100% NPV.
CONCLUSION
The H/M ratio obtained at 3 hours post-injection has the potential to be a novel indicator for ATTR-CA.
Identifiants
pubmed: 36547805
doi: 10.1007/s12350-022-03180-5
pii: 10.1007/s12350-022-03180-5
doi:
Substances chimiques
Technetium Tc 99m Pyrophosphate
5L76I61H2B
Prealbumin
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1374-1381Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
Références
Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJ, Sekijima Y. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018;25:215‐9.
doi: 10.1080/13506129.2018.1549825
pubmed: 30614283
Ruberg FL, Miller EJ. Nuclear tracers for transthyretin cardiac amyloidosis: Time to bone up? Circ Cardiovasc Imaging 2013;6:162‐4.
doi: 10.1161/CIRCIMAGING.113.000178
pubmed: 23512778
Maurer MS, Schwartz JH, Gundapaneni B, Elliot PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐16.
doi: 10.1056/NEJMoa1805689
pubmed: 30145929
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. Circ Cardiovasc Imaging 2021;14:e000029.
pubmed: 34196223
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554‐68.
doi: 10.1093/eurheartj/ehab072
pubmed: 33825853
pmcid: 8060056
Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS.
doi: 10.1161/CIRCIMAGING.112.000132
pubmed: 23400849
pmcid: 3727049
Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1:880‐9.
doi: 10.1001/jamacardio.2016.2839
pubmed: 27557400
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.
doi: 10.1161/CIRCULATIONAHA.116.021612
pubmed: 27143678
Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol 2020;75:2851‐62.
doi: 10.1016/j.jacc.2020.04.022
pubmed: 32498813
Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020;84:1610‐71.
doi: 10.1253/circj.CJ-20-0110
pubmed: 32830187
Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can
doi: 10.1016/j.jcmg.2016.06.003
Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM, et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021;28:1835‐45.
doi: 10.1007/s12350-021-02563-4
pubmed: 33689152
Watanabe S, Nakajima K, Wakabayashi H, Yoneyama H, Yoshida S, Komatsu J, et al. Volumetric evaluation of
doi: 10.1007/s12350-021-02857-7
Ramsay SC, Lindsay K, Fong W, Patford S, Younger J, Atherton J. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging 2018;2:17.
doi: 10.1186/s41824-018-0035-1
pubmed: 30175320
Sperry BW, Vranian MN, Tower-Rader A, Hachamovitch R, Hanna M, Brunken R, et al. Regional variation in technetium pyrophosphate uptake in transthyretin cardiac amyloidosis and impact on mortality. JACC Cardiovasc Imaging 2018;11:234‐42.
doi: 10.1016/j.jcmg.2017.06.020
pubmed: 28917675
Bay K, Gustafsson F, Maiborg M, Bagger-Bahnsen A, Strand AM, Pilgaard T, et al. Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: A systematic literature review. ESC Heart Fail 2022;9:1524‐41.
doi: 10.1002/ehf2.13884
pubmed: 35343098
pmcid: 9065854
Krishnamurthy GT, Huebotter RJ, Walsh CF, Taylor JR, Kehr MD, Blahd WH. Kinetics of 99mTc-labeled pyrophosphate and polyphosphate in man. J Nucl Med 1975;16:109‐15.
pubmed: 162949
Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 2014;113:1723‐7.
doi: 10.1016/j.amjcard.2014.02.030
pubmed: 24698461